Reviva Pharmaceuticals (RVPH) Expected to Announce Quarterly Earnings on Wednesday

Reviva Pharmaceuticals (NASDAQ:RVPH) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.15) per share for the quarter.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. On average, analysts expect Reviva Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Trading Up 9.9%

RVPH stock opened at $0.45 on Tuesday. Reviva Pharmaceuticals has a twelve month low of $0.30 and a twelve month high of $4.28. The company has a market capitalization of $21.48 million, a P/E ratio of -0.57 and a beta of -0.05. The firm has a 50 day simple moving average of $0.53 and a 200-day simple moving average of $0.92.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Reviva Pharmaceuticals in a report on Friday, June 27th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $9.00.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 6.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 448,202 shares of the company’s stock after purchasing an additional 29,063 shares during the quarter. Geode Capital Management LLC owned approximately 0.93% of Reviva Pharmaceuticals worth $171,000 at the end of the most recent quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.